Xontogeny LLC‘s Perceptive Xontogeny Venture Fund, an investment vehicle focused on early-stage, private venture investments in life sciences companies, has led a series A financing round of $35 million for Tellus Therapeutics, a neonatal care company developing treatments for newborns in the neonatal intensive care unit,
The capital will be used to continue preclinical work conducted through the seed investment with the Xontogeny development team and to advance TT-20, the company’s candidate for the treatment of white matter brain injury in preterm infants, as well as the company’s pipeline programs.
“The investment by PXV is bringing Tellus one step closer to delivering first-in-class treatments that improve outcomes for our most vulnerable patient population,” comments Jason Kralic, Tellus co-founder and chief executive officer.